Board of Directors
Adrian Weller, PhD
Senior Research Fellow, University of Cambridge Programme Director, Artificial Intelligence, The Alan Turing Institute
Board Observers
Our Investors









Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
Timothy Thompson is the former Chairman and CEO of Aptus Health, a global digital health company whose core platform, Univadis®, delivers medical news, thought leader education, and conference coverage to over four million healthcare professionals around the world. A wholly owned subsidiary of Merck & Co., Aptus Health was acquired by WebMD in 2019.
Mr. Thompson currently serves as the executive chair of GNS Healthcare and as an advisor to Echo Health Ventures.
Prior to Aptus Health, Mr. Thompson served as the Chairman and CEO of Intervention insights, a health information services company supporting evidence-based care in molecular oncology. Prior to Intervention Insights, Mr. Thompson served as the President and CEO of Proventys, an innovative healthcare technology company that developed web-based decision support solutions in oncology. Before joining Proventys, Mr. Thompson was a business development executive at Aetna, Inc., serving as Managing Director of mergers & acquisitions and the Head of Strategic Business Development for Aetna Health Information Solutions.
Earlier in his career, Mr. Thompson served as the Chief Operating Officer and Vice President of Business Development for PHT Corporation, a privately held mobile data capture and clinical trial software company. He joined PHT after successfully negotiating the sale of Clinical Data Solutions, Inc. where he had been founder and CEO.
Mr. Thompson received a BA in Zoology and Biochemistry from the University of New Hampshire where he was elected into the Phi Beta Kappa honor society.
Janis Naeve, Managing Director of Amgen Ventures, joined Amgen in 2005 and directs the company’s corporate venture capital fund focused on early-stage biotechnology companies discovering and developing human therapeutics as well as digital health and healthcare IT. Janis came to Amgen from X-Ceptor Therapeutics where she was Director of Corporate Development and supported the acquisition by Exelixis. Prior to this she was Director of Business Development at Aurora Biosciences where she led transactions for the ion channel technology business unit and managed the collaborations with Pfizer, Merck, Lilly, and Bristol Myers-Squibb. Janis holds a PhD in pathology from University of Southern California and completed a post-doctoral fellowship at the California Institute of Technology.
Shin Serizawa joined the company in 2003, and has engaged in various projects including its business process reengineering, ERP installation at their overseas office, and building the alliance between the AOL Platforms Japan (which has become Oath Japan) and local internet advertisement agencies in China. He has also taken initiative to form a strategic partnership with Drawbridge in July 2017 and has been working to expand its business in Japanese market since then.
Joel Krikston is Managing Director Venture Investments and Head of Strategic Innovation Alliances. Joel is focused on identifying new investment opportunities with a focus on Oncology, Vaccines and Infectious Disease. Mr. Krikston has over 20 years of experience in healthcare innovation. Prior to joining Merck GHI, he was an Investment Principal at Johnson & Johnson Development Corporation. Joel also spent over eight years as an investment banker, covering an array of healthcare clients and included experience at BNP Paribas, JPMorgan and ABN Amro. Joel has an MBA from the Stern School of Business at NYU and completed his Bachelor’s degree in Finance and International Business at Fairfield University.